- |||||||||| pomalidomide / Generic mfg.
Journal: Pomalidomide-induced lung injury: A case report. (Pubmed Central) - Jan 14, 2023 As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.
- |||||||||| dexamethasone / Generic mfg.
Journal: 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour? (Pubmed Central) - Jan 13, 2023 Therefore, we produced poly(Ɛ-caprolactone) filaments containing different soluble forms of dexamethasone (free acid, DEX; acetate ester, DEX-A; and phosphate salt, DEX-P), which showed suitable mechanical properties and printability...The drug release profiles from the 3D printed forms containing the same drug form but with different sizes were almost completely overlapped. Therefore, these 3D printed matrix solid forms can have their drug content customised by adjusting their size, without changing their controlled release behaviour.
- |||||||||| Darzalex (daratumumab) / J&J, Xpovio (selinexor) / Karyopharm
Enrollment open, Trial completion date, Trial primary completion date: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 13, 2023 P2, N=52, Recruiting, Phase classification: P2 --> P3 Not yet recruiting --> Recruiting | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Sep 2023 --> Dec 2023
- |||||||||| Ruxience (rituximab-pvvr) / Pfizer, Lumoxiti (moxetumomab pasudotox) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Enrollment change: 19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - Jan 13, 2023 P1, N=15, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=30 --> 15
- |||||||||| dexamethasone / Generic mfg.
Covid-19-induced cold agglutinin disease (Virtual) - Jan 13, 2023 - Abstract #HEMATOLOGY2023HEMATOLOGY_40; Our patient did not have any risk factors for cold agglutinin disease except for a COVID-19 infection. Lymphoid malignancies have immunoglobulin that is monoclonal while polyclonal immunoglobulin is prominent during infection.
- |||||||||| fluocinolone acetonide / Generic mfg.
0.19 mg Fluocinolone Acetonide (FAc) Implant Leads to Superior Vision-, Anatomical-, and Treatment Burden-Related Outcomes in Eyes with Better Baseline Visual Acuity (20/40 or better) (Fontainebleau - Miami, FL) - Jan 13, 2023 - Abstract #Macula2023Macula_267; Real world data from the 3-year prospective, phase IV PALADIN study highlights that vision was maintained or improved regardless of baseline visual acuity, and no new safety concerns were identified. PALADIN real world data provides supportive evidence that better seeing eyes at baseline (>20/40), compared to worse seeing eyes (<20/40), have superior vision, anatomy, and reduced treatment burden when treated with the 0.19 mg FAc implant.
- |||||||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis, Avastin (bevacizumab) / Roche
Targeted Multi-modality Treatment Eliminates the need for Enucleation in Complex Coats’ Disease (Fontainebleau - Miami, FL) - Jan 13, 2023 - Abstract #Macula2023Macula_240; Targeted multi-modality eliminates the need for enucleation in infants and children presenting with advanced Coats’ disease. Correct diagnosis and repetitive treatment are key to preserving anatomic and visual function.For “orphan” diseases translational application of clinical data outside of traditional clinical trials establishes a framework for treatment in the absence of randomized clinical trials
- |||||||||| dexamethasone / Generic mfg., decitabine / Generic mfg.
Sensitisation and eradication of chemo-resistant T-ALL by repurposing epigenetic and non-conventional cancer drugs () - Jan 13, 2023 - Abstract #LCC2023LCC_116; These findings will advance our knowledge of how the epigenetic alterations in drug-resistant T-ALL impact drug sensitivity and ultimately guide patient profiling for predicting their response to this regimen. By using repurposed drugs with safe clinical profiles, the regimen can be rapidly translated to the clinics to improve the outcome of children with hard-to-treat T-ALL.
- |||||||||| dexamethasone / Generic mfg.
The role of PU.1 in mediating glucocorticoid response in acute lymphoblastic leukaemia () - Jan 13, 2023 - Abstract #LCC2023LCC_115; Immune-deficient mice harbouring ALL PDX with PU.1 knock-out (KO), no KO (wild type, WT), or BIM KO (positive control) were treated with the standard preclinical course of Dexamethasone (glucocorticoid) and monitored for leukaemia relapse...Importantly, PU.1 KO alone did not affect leukaemia progression rate, indicating that PU.1 loss is not lethal to ALL survival. Our finding opens a new therapeutic pathway for including PU.1 inhibitors to the standard glucocorticoid chemotherapy regimen and editing of PU.1-bound gene regulatory elements to improve treatment response and patient survival.
- |||||||||| methylprednisolone oral / Generic mfg.
EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL (MR 110 ABC) - Jan 12, 2023 - Abstract #ISNWCN2023ISN_WCN_242; Conclusions Reduced-dose methylprednisolone is effective in delaying major kidney events and improving kidney outcomes in IgAN, with benefits that appear to outweigh the modestly increased risk of steroid-related SAEs compared to placebo. On behalf of the TESTING Trial Steering Committee
- |||||||||| Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
Trial completion: Anti-inflammatory Effects Glycopyrronium (clinicaltrials.gov) - Jan 12, 2023 P3, N=28, Completed, On behalf of the TESTING Trial Steering Committee Active, not recruiting --> Completed
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg.
Journal: Considerations of organ donation among prehospital physicians. (Pubmed Central) - Jan 12, 2023 The mortality was high for patients with DNI orders and respiratory distress with very high levels in supplemental oxygen in both the first and second wave of COVID-19 despite an increase in use of cCPAP and treatment with dexamethasone and remdesivir during the second wave. Hence, careful evaluation on transition to palliative care must be considered for these patients.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Switchable DNA Photocatalysts for Radical Polymerization Controlled by Chemical Stimuli. (Pubmed Central) - Jan 12, 2023 We show these photocatalysts can initiate free-radical polymerization to form bulk hydrogels in response to complementary DNA, a metal ion (Zn), or small molecules (glucose and hydrocortisone)...These results demonstrate that DNA conformational changes triggered by chemically diverse stimuli can regulate the activity of radical polymerization photocatalysts. This platform offers new capabilities in spatially and temporally controlled polymer synthesis, with potential applications in diagnostics, sensing, and environmentally responsive materials.
- |||||||||| dexamethasone / Generic mfg.
Journal: Liposomal Bupivacaine versus Dexamethasone: Reply. (Pubmed Central) - Jan 12, 2023 This platform offers new capabilities in spatially and temporally controlled polymer synthesis, with potential applications in diagnostics, sensing, and environmentally responsive materials. No abstract available
- |||||||||| dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date: Dexamethasone in Total Knee Arthroplasty (clinicaltrials.gov) - Jan 12, 2023 P4, N=429, Recruiting, Initiation date: Dec 2022 --> Mar 2023 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Enrollment open, Trial completion date, Trial primary completion date: Effect of Corticosteroid Injections on Blood Glucose (clinicaltrials.gov) - Jan 12, 2023
P2, N=124, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- |||||||||| HR20013 / Jiangsu Hengrui Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Study of HR20013 for Injection in Patients With Malignant Solid Tumors (clinicaltrials.gov) - Jan 12, 2023 P1, N=24, Active, not recruiting, Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Apr 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- |||||||||| dexamethasone cyclodextrin nanoparticle ophthalmic suspension (OCS-01) / Oculis
Enrollment closed, Trial completion date, Trial primary completion date: Pivotal Study of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-1) (clinicaltrials.gov) - Jan 12, 2023 P2/3, N=497, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Apr 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| Darzalex (daratumumab) / J&J, Ninlaro (ixazomib) / Takeda
Enrollment closed, Enrollment change, Trial completion date: DeRIVE: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jan 12, 2023 P2, N=49, Active, not recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2023 --> Apr 2023 Recruiting --> Active, not recruiting | N=76 --> 49 | Trial completion date: Jul 2024 --> Jul 2025
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Journal, IO biomarker: Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. (Pubmed Central) - Jan 11, 2023 Taken together, these findings uncover a novel mechanism of ponatinib-induced cardiac inflammation leading to cardiac dysfunction. From a translational perspective, our results provide critical preclinical data and rationale for a clinical investigation into immunosuppressive interventions for managing ponatinib-induced cardiotoxicity.
|